Targos Molecular Pathology GmbH and WuXi PharmaTech to Collaborate in Clinical Biomarker Services and Pathology Training in China

Kassel, Germany and Shanghai, China, May 23, 2014: Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced a strategic biomarker collaboration.

Through this collaboration, Targos will provide know-how, services, and the quality standards to support WuXi’s bioanalytical work for pharmaceutical customers.  The collaboration will focus on the validation and analysis of clinical tissue biomarkers in cancer.  Targos will also provide its internationally known training and education to support pathologists and histotechnologists in generating accurate, objective, and reproducible diagnostic results.  By adding these new molecular pathology testing services from Targos, WuXi will provide customers with a comprehensive platform of services in soluble, cell, and tissue biomarkers.


“We are pleased to have found in WuXi a partner who shares our vision of offering customers the highest-quality biomarker services,” said Dr. Thomas Henkel, CEO of Targos.


“This agreement with Targos advances WuXi’s mission of offering our customers the broadest range of capabilities to support their drug development," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.


For further information please contact:

Targos Molecular Pathology GmbH
George L Kumar, PhD, MBA
Vice President of Marketing and Scientific Affairs
+ 1 425 777 6167
+ 49 151 46166805  
George.Kumar@targos-inc.com

WuXi PharmaTech
Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com  

Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com  


About Targos
Targos’s core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry.  The company has supported more than 100 international clinical trials since 1999, which have led to the approval of several targeted therapies and IVDs for our customers.  The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management.  Targos also supports the introduction of new Companion Diagnostic assays into the market. Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA).  Targos Molecular Pathology GmbH is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA). 


About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit www.wuxiapptec.com
 


Targos and AKESOgen form strategic partnership to enable a comprehensive biomarker service for clinical trials and molecular pathology

Kassel, Germany and Norcross, GA, USA. May 21, 2014.  Targos Molecular Pathology GmbH, a leader in clinical biomarker services and AKESOgen Inc., a leading US genomics and personalized medicine services  company today announced a global commercial partnership to offer the pharmaceutical and biotech industry a wide ranging package of traditional pathology and new cutting edge molecular biomarker solutions that provides clients a wide ranging menu of biomarker offerings including IHC, FISH, molecular and cytogenomic options.
 
"We were attracted to AKESOgen because of their outstanding quality and service orientated approach as well as their know how in molecular genetic technologies. The unique partnership with AKESOgen will allow us to expand our comprehensive suite of services that have successfully supported the pharma market for nine years. Through this collaboration, we will be able to better serve all of our customers in the US, with the unmatched quality and value-added services that we have established over the past nine years. " said Dr. Thomas Henkel, CEO of Targos.
 
"Targos is an outstanding leader in Europe in molecular pathology services and teaching. We are delighted with this partnership and to support the high quality services in pathology provided by Targos as well as enable a footprint to operate out of the US.” commented Robert Boisjoli, CEO of AKESOgen.
 
The partnership will harness the combined strengths of both companies. AKESOgen will provide its 14,000  sq. ft site and facilities near Atlanta, GA, USA as well as world class genetic and molecular expertise which will complement the undoubted quality and strengths of Targos’s companion diagnostics, pathology and biomarker capabilities.
 
-ENDS-
 
Contact details
George L. Kumar, PhD, MBA, Vice President of Marketing and Scientific Affairs, Targos, GmbH.
E-mail: George.Kumar@targos-inc.com
 
 
Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.
E-mail: mbouzyk@akesogen.com
 
About Targos: Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry. The company has supported more than 100 international clinical trials since 1999, which have led to the successful approval of several targeted therapies and IVDs for our customers. The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market. Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Targos Molecular Pathology GmbH is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA). 
 
About AKESOgen:  AKESOgen is a CLIA compliant integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. The company supports a number of world class organizations including the CDC, the US Department of Veteran’s Affairs, the American Cancer Society and Kaiser Permanente. AKESOgen’s flagship clinical test is a clinical cytogenomics array for a wide-ranging spectrum of cancers. AKESOgen also provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com